YD Bio (YDES) Non-Current Assets (2024 - 2025)
YD Bio (YDES) posted quarterly Non-Current Assets of -$9670.2 billion for Q4 2025, down 178.85% year-over-year from $12264.0 billion in Q4 2024, and down 217588878.22% quarter-over-quarter from $4.4 million in Q2 2025.
YD Bio (YDES) Non-Current Assets (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Non-Current Assets for 2 consecutive years, with -$9670.2 billion the latest figure, recorded in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | YD Bio | 314.91 Mn | 308.91 Mn | - | -9,670.18 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9,670.18 Bn |
| Jun 30, 2025 | 4.44 Mn |
| Dec 31, 2024 | -3,467.88 Bn |